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ABSTRACT Eukaryal taxa differ with respect to the structure and mechanism of the RNA triphosphatase (RTPase) component of
the mRNA capping apparatus. Protozoa, fungi, and certain DNA viruses have a metal-dependent RTPase that belongs to the
triphosphate tunnel metalloenzyme (TTM) superfamily. Because the structures, active sites, and chemical mechanisms of the
TTM-type RTPases differ from those of mammalian RTPases, the TTMRTPases are potential targets for antiprotozoal, antifun-
gal, and antiviral drug discovery. Here, we employed RNA interference (RNAi) knockdownmethods to show that Trypanosoma
brucei RTPase Cet1 (TbCet1) is necessary for proliferation of procyclic cells in culture. We then conducted a high-throughput
biochemical screen for small-molecule inhibitors of the phosphohydrolase activity of TbCet1. We identified several classes of
chemicals—including chlorogenic acids, phenolic glycopyranosides, flavonoids, and other phenolics—that inhibit TbCet1 with
nanomolar to low-micromolar 50% inhibitory concentrations (IC50s). We confirmed the activity of these compounds, and tested
various analogs thereof, by direct manual assays of TbCet1 phosphohydrolase activity. The most potent nanomolar inhibitors
included tetracaffeoylquinic acid, 5-galloylgalloylquinic acid, pentagalloylglucose, rosmarinic acid, andmiquelianin. TbCet1
inhibitors were less active (or inactive) against the orthologous TTM-type RTPases of mimivirus, baculovirus, and budding yeast
(Saccharomyces cerevisiae). Our results affirm that a TTM RTPase is subject to potent inhibition by small molecules, with the
caveat that parallel screens against TTMRTPases frommultiple different pathogens may be required to fully probe the chemical
space of TTM inhibition.
IMPORTANCE The stark differences between the structure and mechanism of the RNA triphosphatase (RTPase) component of
the mRNA capping apparatus in pathogenic protozoa, fungi, and viruses and those of their metazoan hosts highlight RTPase as a
target for anti-infective drug discovery. Protozoan, fungal, and DNA virus RTPases belong to the triphosphate tunnel metalloen-
zyme family. This study shows that a protozoan RTPase, TbCet1 from Trypanosoma brucei, is essential for growth of the para-
site in culture and identifies, via in vitro screening of chemical libraries, several classes of potent small-molecule inhibitors of
TbCet1 phosphohydrolase activity.
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The m7G cap structure of eukaryal mRNA promotes translationinitiation and protects mRNA from degradation by 5= exori-
bonucleases. All eukaryal species and many eukaryal viruses share
a “classic” three-step capping pathway in which (i) an RNA
triphosphatase (RTPase) removes the -phosphate of the primary
transcript, (ii) an RNA guanylyltransferase transfers GMP from
GTP to the 5=-diphosphate RNA to form a GpppRNA cap, and
(iii) a cap-specific RNA (guanine-N7) methyltransferase adds a
methyl group from S-adenosylmethionine (AdoMet) to the cap
guanine to form the m7GpppRNA structure (1).
Eukaryal taxa differ with respect to the structure and mecha-
nism of the RTPase component of the capping apparatus. Fungi
and protozoa have a metal-dependent RTPase that belongs to the
triphosphate tunnel metalloenzyme (TTM) superfamily (2, 3).
The crystal structure of the Saccharomyces cerevisiae RTPase Cet1
(SceCet1) (4) revealed a novel fold in which the active site is lo-
cated in the center of a topologically closed 8-stranded antiparallel
-barrel (the triphosphate tunnel). The TTM active site is com-
posed of essential amino acids that either coordinate a metal ion or
the -phosphate or stabilize the tunnel architecture (4–7). Bio-
chemical characterization, comparative mutational analyses,
and/or structure determinations by X-ray crystallography have
shown that the RTPases of fungi Candida albicans and Schizosac-
charomyces pombe (8–10); protozoan parasites Trypanosoma bru-
cei (11, 12) Plasmodium falciparum (3, 13), Encephalitozoon cunic-
uli (14), and Giardia lamblia (15); and DNA viruses vaccinia virus
(16, 17), mimivirus (18), baculovirus (19–22), and Chlorella virus
Paramecium bursaria Chlorella virus 1 (PBCV-1) (23, 24) all be-
long to the TTM superfamily. In contrast, metazoan and plant
RTPases are metal-independent enzymes of the cysteine-
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phosphatase superfamily (25, 26), and they catalyze -phosphate
hydrolysis via a covalent protein-cysteinyl-S-phosphoester inter-
mediate (26).
The fact that the tertiary structures, active sites, and chemical
mechanisms of the TTM-type RTPases are completely different
from those of mammalian cysteine-phosphatase-type RTPases
highlights TTM RTPases as promising targets for antifungal, an-
tiprotozoal, and antiviral drug discovery predicated on interdict-
ing the capping of the pathogen’s mRNAs while sparing the host’s
capping pathway (27). The TTM RTPases Cet1, Pct1, and TriA are
essential for the growth of the budding yeast S. cerevisiae, the fis-
sion yeast S. pombe, and the human-pathogenic fungusAspergillus
fumigatus, respectively (5, 28, 29). To our knowledge, it has not
been determined whether a TTM RTPase is essential for a proto-
zoon. Here, we employed RNA interference (RNAi) to show that
T. brucei RTPase Cet1 (TbCet1) is necessary for proliferation of
procyclic cells in culture.
Yeast ceg1 strains that rely for viability on the activity of either
fungal, viral, and protozoan TTM RTPases or mammalian
cysteine-phosphatase RTPases afford enabling tools for cell-based
screens and counterscreens for cytotoxins that inhibit TTM
RTPases (11, 30, 31). In vitro screening for inhibitors of TTM
RTPases is simplified by their signature biochemical property of
hydrolyzing nucleoside triphosphates (NTPs) to nucleoside
diphosphates (NDPs) and inorganic phosphate (Pi) in the pres-
ence of manganese (2), thereby avoiding the need to prepare
triphosphate-terminated RNAs as the substrates.
In the present study, we conducted a biochemical screen for
small-molecule inhibitors of theT. bruceiRTPase TbCet1. Kineto-
plastid protozoan parasites of the genus Trypanosoma are major
zoonotic pathogens of humans. Trypanosoma cruzi is the cause of
Chagas disease, endemic in South America. T. brucei, transmitted
by tsetse flies, causes sleeping sickness in sub-Saharan Africa. The
drugs used to treat trypanosomiasis (pentamidine, suramin, me-
larsoprol, and eflornithine) either are old, have many undesirable
side effects, are not effective against late-stage disease, or are cum-
bersome to administer (32). There is a need for new therapeutic
approaches.
TbCet1 is a 252-amino-acid (aa) monomeric TTM protein that
can function in cap formation in vivo in S. cerevisiae in lieu of yeast
Cet1 (11, 12). Recombinant TbCet1 has vigorous manganese-
dependent ATPase activity (kcat, 59 s1) that is effaced by alanine
mutations of conserved active site residues in the triphosphate
tunnel. TbCet1 is exceptionally thermostable. Tripolyphosphate
is a potent competitive inhibitor of TbCet1 (Ki, 1.4M) that binds
more avidly to the active site than the ATP substrate (Km, 25M).
Synergistic activation of the TbCet1 triphosphatase by manganese
and magnesium suggested a two-metal mechanism of catalysis
(12). Recent crystallographic studies of other TTM family mem-
bers indicate that two-metal catalysis is a core feature of the TTM
clade (33).
Here, we implemented a colorimetric assay of phosphate re-
lease from ATP by TbCet1 for the purpose of high-throughput
screening (HTS) for small-molecule inhibitors. The initial ques-
tions were (i) can potent TbCet1 inhibitors be identified, and (ii)
if so, do they illuminate common features? The answer to both
questions is yes, as described below. Part of the allure of TTM
RTPases as anti-infective drug targets is the prospect of obtaining
an inhibitor with broad-spectrum potency against fungal, proto-
zoal, and viral RTPases. To put this idea to the test, we surveyed
the newly identified inhibitors of TbCet1 for their effects on ex-
emplary fungal and viral TTM RTPases and on a non-RTPase
bacterial TTM enzyme (34, 35). The results indicated that the
inhibitors generally displayed greatest potency and selectivity for
the TbCet1 enzyme against which they were screened, signifying
that parallel screening against TTM RTPases from pathogens of
interest may be required to best explore the chemical space of
TTM inhibition.
RESULTS
Inducible RNAi knockdown of TbCet1 arrests the growth of
T. brucei in culture. TbCet1 was depleted in T. brucei procyclic
cells by using an RNAi system in which the synthesis of double-
stranded TbCet1 RNA by T7 RNA polymerase is tetracycline in-
ducible. In the experiment shown in Fig. 1A, the cells were inoc-
ulated into medium containing 1.0 g/ml tetracycline (Tet) to
induce TbCet1 double-stranded RNA (dsRNA) production and
into a parallel control culture lacking tetracycline (Tet). The
control uninduced cells maintained logarithmic growth over a
14-day period. In contrast, the induction of TbCet1 RNAi by Tet
acutely curtailed cell proliferation after an initial 5-day interval of
logarithmic growth. RNAi depletion of cellular TbCet1 protein
was verified by Western blot analysis of total protein from Tet
FIG 1 RNAi knockdown of TbCet1 arrests growth of T. brucei. (A) Procyclic
T. brucei 29.13-TbCet1RNAi transfectants were inoculated into medium con-
taining 1.0 g/ml tetracycline (Tet) to induce TbCet1 dsRNA production
and into a parallel control culture lacking tetracycline (Tet). Cell density was
monitored by microscopy and maintained between 1  106 and 1  107
cells/ml by dilution into fresh medium. The growth curves display on the y axis
the log of the direct cell count multiplied by the dilution factor. Induction of
RNAi against TbCet1 arrested T. brucei growth after 5 days. (B) Western blot-
ting verifies knockdown of TbCet1 protein by RNAi induction. An anti-
TbCet1 immunoblot assay of total protein from cells harvested from a Tet
culture is shown. The positions and sizes (kilodaltons) of marker polypeptides
are indicated on the left. The immunoreactive TbCet1 polypeptide, denoted by
the arrowhead at left, is depleted after RNAi induction. A nonspecific cross-
reacting 50-Da polypeptide, indicated by the asterisk at right, is unchanged.
Smith et al.
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cells (Fig. 1B). The level of TbCet1 protein was serially decreased
to 26% of the initial value after 1 day of incubation in tetracycline,
to 12% after 2 days, and to8% for the rest of the 14-day period
of RNAi induction. These results indicate that TbCet1 is essential
for T. brucei growth, and they encourage screening for TbCet1
inhibitors as potential antitrypanosomal drugs.
Test library screening for inhibitors of TbCet1 ATPase. We
applied a colorimetric assay using malachite green reagent to
gauge the release of inorganic phosphate from ATP by recombi-
nant TbCet1 in the presence of manganese. The Z= score for this
assay was 0.88. Z= is a measure of the signal-to-noise ratio intrinsic
to an experiment and is calculated by comparing the typical vari-
ance in values for positive and negative controls with the dynamic
range seen between the two. Values above 0.5 indicate that an
assay is well suited for high-throughput screening (36).
The susceptibility of TbCet1 to chemical inhibition was tested
via an initial screen of a library of 2,879 structurally diverse com-
pounds comprising pharmaceuticals, natural products, and in-
dustrial chemicals. We identified 22 compounds from this collec-
tion that reproducibly inhibited the TbCet1 ATPase activity by
75% at a 10 M concentration (Table 1). Nineteen of the 22
inhibitors were phenolic compounds that fell into discrete chem-
ical classes, either flavonoids (11/22), phenolic glucopyranosides
(2/22), or nonflavonoid phenolics (6/22). The chemical structures
of the flavonoids and selected phenolics are shown in Fig. 2. In a
previous study (37), a screen of the same test library for TbCet1
ATPase inhibitors using a fluorescence polarization-based assay
(Transcreener) for detection of ADP formation yielded 23 con-
firmed positives with 50% inhibitory concentrations (IC50s) of
less than 10M. Sixteen of the TbCet1 inhibitors identified in the
present screen using a phosphate release assay were identified in-
dependently by assaying inhibition of ADP release.
HTS for TbCet1 inhibitors. We next applied the colorimetric
high-throughput screening (HTS) assay to survey 191,050 com-
pounds sourced from four different commercial libraries, of
which 543 (0.28%) inhibited the ATPase activity of TbCet1 by at
least 50% at a 10 M concentration. A set of 216 nonredundant
compounds were resupplied by the vendors, 83 (38%) of which
showed reproducible inhibition of TbCet1 upon retesting and
were thus designated confirmed “hit” compounds. The hit com-
pounds were then subjected to IC50 determination via the HTS
assay. Nine compounds had IC50s of 1.1 M or less (Table 2).
These were, in decreasing order of potency, 1,3,4,5-O-
tetracaffeoylquinic acid (compound 1A; IC50, 20 nM); 3,5-O-
dicaffeoylquinic acid (compound 1B; IC50, 40 nM); pentagalloyl-
glucose (compound 2A, IC50, 40 nM); rosmarinic acid
(compound 3A; IC50, 50 nM); three flavonoids, miquelianin (com-
pound 4A; IC50, 180 nM), myricetin (compound 4B; IC50, 230 nM),
and epicatechin (compound 4C; IC50, 260 nM); 3-hydroxy-1-(4-
hydroxyphenyl)propan-1-one (compound 5; IC50, 630 nM); and
3-O-(4-hydroxyphenylpropanone)-1-glucopyranoside (compound
2B; IC50, 1.1 M). Chemical structures of the constituents of these
compounds are shown in Fig. 2 and 3.
Each of these nine compounds was then retested for TbCet1
inhibition via a direct assay of the release of 32Pi from [-32P]ATP,
in which the reaction products were analyzed by polyethylenei-
mine (PEI)-cellulose thin-layer chromatography (TLC). Loga-
rithmic plots of inhibition versus compound concentration are
shown in Fig. 4 for tetracaffeoylquinic acid (compound 1A; IC50,
13 nM) and rosmarinic acid (compound 3A; IC50, 120 nM), as
well as for three less potent compounds (to be discussed below).
The IC50s for the radiolabeled ATP hydrolysis assay agreed fairly
well with those from the colorimetric phosphate release assay em-
ployed for HTS (Table 2). In the radioactive phosphate release
assay, the TbCet1, ATP, and Mn2 concentrations were 2.2 nM,
0.2 mM, and 2 mM, respectively. Thus, the nanomolar to micro-
molar inhibition observed for the 9 hit compounds cannot be
attributable to sequestration of metal cofactor or nucleotide sub-
strate. The direct radiolabel phosphate release assay was employed
for all further studies.
Inhibition of TbCet1 by chlorogenic acids and their deriva-
tives.Chlorogenic acids are compounds wherein cinnamic acid or
one of its derivatives is esterified to a quinic acid scaffold (Fig. 3).
Chlorogenic acids often contain multiple ester substitutions on
the quinic acid hydroxyl groups. The two most potent inhibitors
of TbCet1 identified by HTS were the chlorogenic acids tetra-
caffeoylquinic acid (compound 1A) and 3,5-dicaffeoylquinic acid
(compound 1B). Caffeic acid is the dihydroxy derivative of cin-
namic acid (Fig. 3). To ascertain the inhibitory properties of com-
pounds similar to these, we screened an additional 14 chlorogenic
acids and 4 structurally related quinic acid esters for inhibition of
TbCet1 (compounds 1C to 1T [Table 3]). Four of these com-
pounds (1D, 1E, 1G, and 1T) contained caffeic acid substituents.
Two compounds (1I and 1Q) contained cinnamic acid. Eight oth-
ers (1H, 1J, 1L, 1M, 1N, 1P, 1R, and 1S) included three different
derivatives of cinnamic acid: coumaric acid, ferulic acid, and
p-ferulic acid (chemical structures shown in Fig. 3). Coumaric
acid differs from caffeic acid by the removal of the meta hydroxyl
moiety. Ferulic acid and p-ferulic acid are O-methyl derivatives of
caffeic acid at the meta and para positions, respectively (Fig. 3).
Though not chlorogenic acids, the 4 additional quinic acid esters
had related phenolic substituents in place of a cinnamic acid de-
TABLE 1 TbCet1 inhibitors identified in the initial test screen of a
2,879-compound library
Class Name
Flavonoid Irigenol
Irigenol hexaacetate
Myricetin
Epigallocatechin-3-monogallate
2=,2=-Bis-epigallocatechin monogallate
Epigallocatechin digallate
Epicatechin monogallate
Theaflavin monogallate
Theaflavanin
Rhamnetin
Quercetin
Phenolic Pyrogallin
Purpurogallin
Ellagic acid
Hematein
Norepinephrine
Chicago sky blue 6B
Phenolic glucopyranoside Tannic acid
Sennoside A
Other Merbromin
N-Hydroxymethyl-nicotinamide
Gangleoidin acetate
Inhibitors of Trypanosoma brucei RNA Triphosphatase
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rivative. These were gallic acid (3,4,5-trihydroxybenzoic acid
[Fig. 3]) in compounds 1F and 1O; m-galloyl gallic acid (a dimer
of gallic acid [Fig. 3]) in compounds 1C and 1F; and benzoic acid
in compound 1K. Whereas none of these 18 compounds were
better inhibitors than tetracaffeoylquinic acid (compound 1A)
and 3,5-dicaffeoylquinic acid (compound 1B), five of the quinic
acid esters displayed IC50s below 1 M (compounds 1C, 1D,
1E, 1F, and 1G). These were the quinic acid monoester to
m-galloylgallic acid (at position R-5; IC50, 110 nM), 3,4,5- and
1,3,5-triesters to caffeic acid (IC50s, 150 nM and 190 nM, respec-
tively), and mixed 3-galloyl,5-galloylgalloylquinic acid diester
(IC50, 220 nM). Four of the quinic acid esters had IC50s between 1
and 10 M: the 3,4-dicoumarolyl compound 1H (IC50, 1.3 M);
the 1,3,4,5-tetracinnamoyl compound 1I (IC50, 1.6 M [Fig. 4]);
the 5-p-feruloyl compound 1J (IC50, 2.4 M); and the 1,3,4,5-
tetrabenzoyl compound 1K (IC50, 5.8 M).
FIG 2 Chemical structures of flavonoid TbCet1 inhibitors and related compounds. Core scaffolds of flavonoids are labeled in lightface. TbCet1 inhibitors
identified in the present study are labeled in boldface (with R groups in parentheses as specified). Arrows signify progressive chemical modifications.
Smith et al.
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Rosmarinic acid (compound 3A) resembles a chlorogenic acid
but contains no central scaffold analogous to quinic acid; rather,
rosmarinic acid can be considered a partially hydrogenated dimer
of caffeic acid. Whereas rosmarinic acid inhibited TbCet1 with an
IC50 of 120 nM, a simple caffeic acid monomer (compound 3B)
had an IC50 of 29M (Fig. 4). Quinic acid showed no inhibition of
TbCet1, nor did gallic acid.
Structure-activity relationships for chlorogenic acids. The
importance of both the size of the quinic acid ester substituents
and their content of hydroxyl groups is underscored by compar-
ing 5-galloylquinic acid (compound 1O; IC50, 125 M) with
5-galloyl-galloylquinic acid (compound 1C; IC50, 110 nM),
whereby the latter is 1,100-fold more potent than the former as a
TbCet1 inhibitor. Correlation between substituent size and hy-
droxyl content is also evident when all hydroxy groups are sub-
tracted from the most potent inhibitor, tetracaffeoylquinic acid
(compound 1A; IC50, 13 nM), to yield the 120-fold-less-potent
tetracinnamoylquinic acid (compound 1I; IC50, 1.6 M). This
theme is fortified by comparing 3,5-dicaffeoylquinic acid (com-
pound 1B; IC50, 70 nM) with 3,5-dicoumaroylquinic acid (com-
pound 1M; IC50, 24 M), whereby the subtraction of one meta
hydroxyl group on each of the esterified substituents results in a
340-fold drop in the potency of TbCet1 inhibition.
Hydroxyl content per se is not predictive of potency for the
5-O-monoesters of quinic acid. In this series, a 5-caffeoyl group in
compound 1T (2 hydroxyls) conferred no activity (IC50,
500M), and a 5-galloyl moiety in compound 1M (3 hydroxyls)
and a 5-cinnamoyl group (no hydroxyls) in compound 1Q con-
ferred similarly feeble inhibition (IC50, 125 to 210 M), whereas
5-feruoylquinic acid (compound 1L; IC50, 12 M) and 5-p-
feruoylquinic acid (compound 1J; IC50, 2.4M) were much more
potent. The comparison of inactive 5-caffeoylquinic acid with ac-
tive 5-feruoyl and 5-feruoyl derivatives illustrates the salutary ef-
fect of a methoxy group versus a hydroxyl at the meta or para
positions. The position of monoesterification to the quinic acid
scaffold is highlighted as a governor of inhibitor potency in the
series of feruoylquinic acid isomers, whereby 4-feruoylquinic acid
(compound 1P; IC50, 160 M) is 13-fold less effective than
5-feruoylquinic acid and 1-feruoylquinic acid (compound 1R) is
inactive.
Test of inhibitionbyquinide and shikimic acid esters.Quinic
acid can be derivatized to a gamma lactone by formation of a cyclic
ester of the 1-carboxylic acid and 3-hydroxy groups to give a 1-3
quinic acid lactone, colloquially dubbed a “quinide.” (Contro-
versy exists as to the nomenclature of the resulting lactone [shown
in Fig. 3], but the convention employed here employs the “cis
before trans” rule of the Cahn-Ingold-Prelog naming system, and
thus, the lactone under consideration is termed a 1-3 lactone, not
a 1-5 lactone.) The 1,4,5-tricaffeoyl derivative of quinide (com-
pound 6A [Table 4]) was a potent inhibitor of TbCet1 (IC50,
120 nM), similar to the tricaffeoyl esters of quinic acid (com-
pounds 1D and 1E [Table 3]). Substituting acetate for the R1
caffeic acid in the quinide ester (compound 6C) lowered potency
by 30-fold (IC50, 3.6 M). Quinic acid can also undergo a dehy-
dration reaction at C-1 to form shikimic acid (Fig. 3). We found
that 3,4,5-tricinnamoylshikimic acid (compound 6B) inhibited
TbCet1 with an IC50 of 1.5 M (Table 4), similar to the IC50 of
1.6 M for the tetracinnamoyl ester of quinic acid (compound 1I
[Fig. 3; Table 3]). The derivatives 3,5-dicannamolylshikimate
(compound 6D) and 5-caffeoylshikimate (compound 6E) did not
inhibit TbCet1 (Table 4).
Selectivity of TbCet1 inhibitors. The promise of TTM
RTPases as anti-infective drug targets would be greatest if one
could identify inhibitors with broad-spectrum potency against
fungal, protozoal, and viral TTM RTPases. To see if this property
applied to any of the submicromolar TbCet1 inhibitors identified
currently, we surveyed their effects on (i) S. cerevisiaeCet1; (ii) the
RNA triphosphatase component of mimivirus capping enzyme
(MimiCE) (18); (iii) the RNA triphosphatase component of the
baculovirus Autographa californica nucleopolyhedrovirus
(AcNPV) capping enzyme Lef4 (20–22); and (iv)Clostridium ther-
mocellum TTM (CthTTM), a bacterial TTM family member that
hydrolyzes inorganic polyphosphates, NTPs, and dinucleotide
polyphosphate substrates (34, 35). The IC50s of 25 compounds
against the five ATPase enzymes surveyed are compiled in Table 5.
Tetracaffeoylquinic acid (compound 1A), the most potent of
the TbCet1 inhibitors (IC50. 13 nM), cross-inhibited all of the
other enzymes (Fig. 5), albeit with much lower potency in the
following hierarchy: 110-fold lower against MimiCE (1.4 M),
440-fold lower against Lef4 (5.7 M), 550-fold lower against
SceCet1 (7.1 M), and 850-fold lower against CthTTM (11 M).
3,4,5-Tricaffeoylquinic acid (compound 1D; IC50, 150 nM for
TbCet1) cross-inhibited with similar trends: 48-fold lower against
Lef4 (7.2 M), 67-fold lower against SceCet1 (10 M), 107-fold
lower against MimiCE (16 M), and 1,100-fold lower against
CthTTM (160 M). Galloyl-galloylquinic acid (compound 1C),
with an IC50 of 110 nM versus TbCet1, was inactive against
MimiCE, SceCet1, and CthTTM (IC50,500 M) and only weakly
active against Lef4 (IC50, 75 M; i.e., 680-fold less active com-
pared with its effect on TbCet1). Thus, these three quinic acid
ester compounds are quite specific for TbCet1 among the TTM
enzyme family enzymes tested. Similar trends are seen for other
TABLE 2 Submicromolar TbCet1 inhibitors identified via HTS and confirmed by manual assay
Compound Name Class
IC50 (M) by assay:
HTS 32P
1A Tetracaffeoylquinic acid Quinic acid ester 0.02 0.013
1B 3,5-Dicaffeoylquinic acid Quinic acid ester 0.04 0.07
2A Pentagalloylglucose Glucopyranoside 0.04 0.046
2B 3-O-(4-Hydroxyphenylpropanone)-1-glucopyranoside Glucopyranoside 1.1 0.66
3A Rosmarinic acid Phenolic 0.05 0.12
4A Miquelianin Flavonoid 0.18 0.18
4B Myricetin Flavonoid 0.23 0.36
4C Epicatechin Flavonoid 0.26 0.25
5 3-Hydroxy-1-(4-hydroxyphenyl)propan-1-one Phenolic 0.63 0.64
Inhibitors of Trypanosoma brucei RNA Triphosphatase
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quinic acid ester inhibitors of TbCet1: 1,3,5-tricaffeoylquinic acid
(compound 1E), 3-galloyl,5-galloyl-galloylquinic acid (com-
pound 1F), 1,3-dicaffeoylquinic acid (compound 1G), 3,4-
dicoumaroylquinic acid (compound 1H), and others in Table 5.
An interesting exception was 5-galloylquinic acid (compound
1O), which was a very weak TbCet1 inhibitor (IC50, 125 M) but
emerged as a selective and modestly potent SceCet1 inhibitor
(IC50, 10 M) that had no activity against MimiCE, Lef4, or
CthTTM (Table 5).
Of the two quinide ester TbCet1 inhibitors, the more potent
1,4,5-tricaffeoylquinide (compound 6A; IC50, 120 nM) was 110-
to 240-fold less effective against other TTM enzymes. The less potent
1-acetyl,4,5-dicaffeoylquinide (compound 6C; IC50, 3.6 M) was
also the least specific, with IC50s ranging from just 4-fold to 13-fold
greater against the four other TTM ATPases. Tricinnamoylshikimate
(compound 6B), with an IC50 of 1.5 M versus TbCet1, was 7- to
13-fold less active against Lef4 and MimiCE, 100-fold less ac-
tive against CthTTM, and inactive against SceCet1.
FIG 3 Chemical structures of chlorogenic acid TbCet1 inhibitors and related compounds. Core scaffolds of quinic acid, quinide, and shikimic acid are depicted
in the box at left. Nine substituents esterified to the scaffolds are shown in the top and middle rows. The structures of tetracaffeoylquinic acid and rosmarinic acid
are shown at bottom.
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Pentagalloylglucose (compound 2A) was the second most po-
tent antagonist of TbCet1 identified via our HTS screen (IC50,
46 nM). (A related glucopyranoside tannic acid [pentagalloylgal-
loylglucose] was identified as a TbCet1 inhibitor [IC50, 60 nM] in
the small-scale test library screens performed here and previously
[37].) Pentagalloylglucose inhibited the other enzymes with much
lower potency in the following order: 30-fold lower against
CthTTM (1.4 M), 70-fold lower against SceCet1 (3.2 M), 110-
fold lower against MimiCE (5.1M), and 1,300-fold lower against
Lef4 (150 M). 3-O-(4-Hydroxyphenylpropanone)-1-gluco-
pyranoside (compound 2B), which inhibited TbCet1 with an IC50
of 660 nM, has a cross-inhibitory spectrum similar to that of
pentagalloylglucose against three of the other enzymes: 44-fold
lower against CthTTM (29 M), 62-fold lower against SceCet1
(41M), and 180-fold lower versus MimiCE (120M). It is note-
worthy that 3-hydroxy-1-(4-hydroxyphenyl)propan-1-one itself
(compound 5), which was as effective as 3-O-(4-hydro-
xyphenylpropanone)-1-glucopyranoside versus TbCet1 (IC50,
640 nM), differed from the glucopyranoside in that 3-hydroxy-1-
(4-hydroxyphenyl)propan-1-one had no effect on SceCet1.
Rosmarinic acid (compound 3A), with an IC50 of 120 nM ver-
sus TbCet1, inhibited the other enzymes tested with IC50s ranging
from 1.5 to 4.3 M (i.e., 13- to 36-fold less than against TbCet1).
Caffeic acid monomer (compound 3B), which weakly inhibited
TbCet1 (IC50, 29M) and Lef4 (IC50, 75M), was even less active
against CthTTM (310 M) and inactive against MimiCE and
SceCet1.
The flavonoid inhibitors of TbCet1 miquelianin (compound
4A; IC50, 180 nM), myricetin (compound 4B; IC50, 360 nM), and
epicatechin (compound 4C; IC50, 250 nM) were 40- to 110-fold
less active against MimiCE, 35- to 240-fold less active against
SceCet1, 18- to 26-fold less potent against CthTTM, and 140- to
440-fold less effective against Lef4.
DISCUSSION
The present study affirms that a protozoan TTM RTPase, TbCet1
fromT. brucei, is essential for growth of the parasite in culture and
is subject to inhibition in vitro by small molecules at low-
micromolar and nanomolar concentrations. Applying HTS meth-
ods to an in-house library of nearly 200,000 compounds, we have
identified several classes of chemicals (including chlorogenic ac-
ids, phenolic glycopyranosides, flavonoids, and other phenolics)
that inhibit TbCet1. We subsequently confirmed the activity of the
HTS hits, and various analogs thereof, by direct manual assays of
phosphohydrolase activity.
The majority of the TbCet1 inhibitors that we identified
showed strong specificity for the trypanosome enzyme and were
manyfold less active (or inactive in some cases) against the or-
thologous TTM-type RTPases of mimivirus, baculovirus, and
budding yeast (or the homologous bacterial phosphohydrolase
CthTTM). Thus, (i) potent inhibition of a particular RTPase is no
guarantee that the inhibitory compounds will have a quantita-
tively similar effect on another member of the TTM family, and
(ii) an optimal search for inhibitors of the TTM-type mRNA cap-
TABLE 3 Quinic acid esters tested for inhibition of TbCet1
Compound R1 R3 R4 R5 IC50 (M)
1A Caffeic acid Caffeic acid Caffeic acid Caffeic acid 0.013
1B Caffeic acid Caffeic acid 0.07
1C m-Galloyl-gallic acid 0.11
1D Caffeic acid Caffeic acid Caffeic acid 0.15
1E Caffeic acid Caffeic acid Caffeic acid 0.19
1F Gallic acid m-Galloyl-gallic acid 0.22
1G Caffeic acid Caffeic acid 0.34
1H Coumaric acid Coumaric acid 1.3
1I Cinnamic acid Cinnamic acid Cinnamic acid Cinnamic acid 1.6
1J p-Ferulic acid 2.4
1K Benzoic acid Benzoic acid Benzoic acid Benzoic acid 5.8
1L Ferulic acid 12
1M Coumaric acid Coumaric acid 24
1N Coumaric acid 25
1O Gallic acid 125
1P Ferulic acid 160
1Q Cinnamic acid 210
1R Ferulic acid 500
1S Coumaric acid 500
1T Caffeic acid 500
FIG 4 Potency spectrum of TbCet1 inhibitors. Dose-response profiles for
tetracaffeoylquinic acid (1A), rosmarinic acid (3A), tetracinnamoylquinic acid
(3I), caffeic acid (3B), and 3-O-coumeroylquinic acid (1P). IC50s (M) are
indicated in parentheses.
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ping enzymes of infectious pathogens will entail screening against
RTPases from each organism or virus of interest.
From the data in Table 5, we can infer certain trends in the
responsiveness of other TTM enzymes to TbCet1 inhibitors. For
example, SceCet1 was the least responsive, insofar as 13/25
TbCet1 inhibitors had no effect on the yeast enzyme (IC50,
500 M). MimiCE was unaffected by 7/25 inhibitors. CthTTM
was also unaffected by 7/25 inhibitors, six of which overlapped
with the compounds inactive against MimiCE. Lef4 was unaf-
fected by 5/25 inhibitors, all five of which were also inactive versus
MimiCE and CthTTM.
The classes of compounds that we highlight as TbCet1 inhibi-
tors are not new to the world of medicinal chemistry or pharma-
cology. Diverse bioactivities of potential therapeutic value (e.g.,
antioxidant, anti-inflammatory, antitumor, and antimicrobial ac-
tivities) have been described for caffeoylquinic acids (38), ros-
marinic acid (39), pentagalloylglucose (40), and flavonoids (41,
42). A few of the TbCet1 inhibitors have been tested for cytotoxic
activity against kinetoplastid protozoa. For example, 3,5-
dicaffeoylquinic acid was reported to be inactive against Leishma-
nia amazonensis and Trypanosoma cruzi amastigotes (43). How-
ever, a mixture of 3,4-, 3,5-, and 4,5-dicaffeoylquinic acids was
active against T. cruzi trypomastigotes (44).
We conducted preliminary studies on the effects of tetra-
caffeoylquinic acid and rosmarinic acid on cultured procyclic
T. brucei and found that exposure to 10 M tetracaffeoylquinic
acid or 10 M rosmarinic acid had no effect on cell proliferation
(data not shown). The lack of antitrypanosomal activity of tetra-
caffeoylquinic acid and rosmarinic acid could arise from either
poor cellular uptake of the compounds, rapid efflux of the com-
pounds, or their rapid intracellular catabolism.
Critical insights into the basis for TbCet1 inhibition by the
various classes of phenolic compounds would be afforded by a
crystal structure of RTPase-inhibitor complexes. However, our
strenuous efforts to crystallize TbCet1, as apoenzyme, or in com-
plex with Mn2 and/or ATP, or as inhibitor complexes with tet-
racaffeoylquinic acid or rosmarinic acid, have not met with suc-
cess. Absent an atomic structure, we speculate that small-molecule
inhibition of TbCet1 (or other TTM enzymes) could entail plug-
ging of the entrance of the triphosphate tunnel to prevent ingress
of NTP or triphosphate-terminated RNA to the active site within
the tunnel cavity.
MATERIALS AND METHODS
Inducible RNAi knockdown of TbCet1. TbCet1 was depleted inT. brucei
by using a tetracycline-inducible RNAi system as described previously
(45). A 352-bp DNA fragment of the TbCET1 open reading frame (from
nucleotides 19 to 371) was PCR amplified and inserted into the p2T7-177
vector (46), wherein expression of double-stranded RNA is under the
control of opposing tetracycline-inducible bacteriophage T7 promoters.
The RNAi construct was electroporated into procyclic T. brucei 29.13
cells, which constitutively express T7 RNA polymerase and Tet repressor
(47). The procyclic cell line was cultivated in SDM 79 medium supple-
mented with 5% fetal bovine serum, 50 g/ml hygromycin B, and
15g/ml G418, and the TbCet1-RNAi transfectants were selected with the
TABLE 4 Quinide and shikimate esters tested for inhibition of TbCet1
Compound Modification R1 R3 R4 R5 IC50 (M)
6A Quinide Caffeic acid Caffeic acid Caffeic acid 0.12
6B Shikimate Cinnamic acid Cinnamic acid Cinnamic acid 1.5
6C Quinide Acetate Caffeic acid Caffeic acid 3.6
6D Shikimate Cinnamic acid Cinnamic acid 500
6E Shikimate Caffeic acid 500
TABLE 5 Selectivity of inhibition of TbCet1 versus other TTM
triphosphatases
Compound
IC50, M (IC50/IC50 TbCet1)
TbCet1 MimiCE SceCet1 CthTTM Lef4
1A 0.013 1.4 (108) 7.1 (546) 11 (846) 5.7 (438)
1C 0.11 500 500 500 75 (682)
1D 0.15 16 (107) 10 (67) 160 (1,067) 7.2 (48)
1E 0.19 8.4 (44) 29 (153) 33 (174) 5.6 (29)
1F 0.22 3.4 (15) 500 21 (95) 33 (150)
1G 0.34 3.7 (11) 500 55 (162) 22 (65)
1H 1.3 52 (40) 500 500 140 (108)
1I 1.6 17 (11) 500 17 (11) 6 (4)
1J 2.4 500 500 500 500
1K 5.8 20 (3) 500 72 (12) 46 (8)
1L 12 500 500 500 500
1M 24 500 500 500 500
1N 25 500 500 500 500
1O 125 500 10 (0.08) 500 500
2A 0.046 5.1 (111) 3.2 (70) 1.4 (30) 59 (1,283)
2B 0.66 120 (182) 41 (62) 29 (44) 150 (227)
3A 0.12 4.3 (36) 3.3 (28) 1.5 (13) 3.2 (27)
3B 29 500 500 310 (11) 75 (3)
4A 0.18 19 (106) 43 (239) 24 (133) 29 (161)
4B 0.36 20 (56) 26 (72) 6.5 (18) 160 (444)
4C 0.25 10 (40) 8.7 (35) 26 (104) 34 (136)
5 0.64 84 (131) 500 9.2 (14) 160 (250)
6A 0.12 2 (17) 2 (17) 6.4 (53) 2.6 (22)
6B 1.5 19 (13) 500 150 (100) 10 (7)
6C 3.6 15 (4) 14 (4) 46 (13) 21 (6)
FIG 5 Tetracaffeoylquinic acid activity against five TTM family ATPases.
Dose-response profiles for tetracaffeoylquinic acid inhibition of the indicated
TTM enzymes. IC50s (M) are indicated in parentheses.
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same medium plus 2.5 g/ml phleomycin. To gauge the effects of induc-
ible RNAi knockdown of TbCet1 on cell proliferation, equal aliquots of
the transfectants were inoculated into medium containing 1.0 g/ml tet-
racycline (Tet) to induce TbCet1 dsRNA production and into a parallel
control culture lacking tetracycline (Tet). Cell density over a 14-day
period was monitored by microscopy and was maintained between 1 
106 and 1  107 cells/ml by dilution into fresh medium. Growth curves
(Fig. 1A) display on the y axis the log of the direct cell count multiplied by
the dilution factor.
Cellular levels of TbCet1 during RNAi induction were gauged by
Western blotting as follows. Aliquots (30 g of protein) of whole-cell
lysates of TbCet1-RNAi transfectants harvested prior to addition of tetra-
cycline (day 0) and after 1, 2, 6, 10, or 14 days of exposure to tetracycline
were resolved by 12% SDS-PAGE. The polypeptides were transferred to a
polyvinylidene difluoride membrane. TbCet1 was detected by incubating
the membrane in a 1:500 dilution of affinity-purified rabbit polyclonal
serum raised against recombinant TbCet1 protein (at Pocono Rabbit
Farm and Laboratory, PA), followed by a 1:5,000 dilution of horseradish
peroxidase-conjugated secondary antibody. Immune complexes were vi-
sualized by using an enhanced chemiluminescence (ECL) kit from Pierce.
The intensity of the immunoreactive TbCet1 polypeptide was determined
by scanning the autoradiogram with a Kodak Gel Logic 100 system and
quantifying the signal intensity with molecular imaging software.
Recombinant TTM proteins. Recombinant full-length T. brucei
RTPase TbCet1 (11, 12), the N-terminal RTPase domain (amino acids
[aa] 1 to 237) of mimivirus capping enzyme (MimiCE) (18), the
N-terminal RTPase domain (aa 1 to 236) of AcNPV Lef4 capping enzyme
(21), the biologically active C-terminal catalytic domain (aa 241 to 539) of
S. cerevisiae RTPase (SceCet1) (4), and full-length C. thermocellum TMM
(CthTTM) (34) were produced in Escherichia coli and purified as de-
scribed in the publications cited. TbCet1, MimiCE, Lef4, and CthTTM
were produced as N-terminal HisSmt3-tagged fusions, and SceCet1 was
produced as an N-terminal His-tagged fusion. After nickel-affinity puri-
fication of the tagged proteins from soluble bacterial lysates, the HisSmt3
tags were removed by the Smt3 protease Ulp1, and the tag-free recombi-
nant proteins were recovered in the flowthrough fraction during a second
round of nickel-affinity chromatography. The tag-free enzymes and His-
tagged SceCet1 were further purified by gel filtration through a HiPrep
Sephacryl S300 size exclusion column (GE Healthcare) equilibrated in
buffer C (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10% glycerol, 0 to
5 mM dithiothreitol [DTT]). Peak fractions were pooled and adjusted to
attain solutions of 10 M TbCet1, 35 M MimiCE, 42 M SceCet1,
500 M CthTTM, and 7 M Lef4. The proteins were stored at80°C in
single-use aliquots.
HTS assay for inhibitors of TbCet1 ATPase. The high-throughput
screening (HTS) assay was based on the detection of Pi release from ATP
via the use of malachite green reagent. Pi is quantified by measuring the
A630 of a chromophore complex formed by malachite green and phospho-
molybdate. For HTS procedures, 1 l of test compound in 10% dimethyl
sulfoxide (DMSO) was predispensed into flat-bottomed transparent 384-
well plates to which was added 4 l of ATPase master mix containing the
following reagents to attain the final concentrations indicated: 50 mM
Tris-HCl (pH 8.0), 20 mM MgCl2, 2 mM DTT, 4 mM MnCl2, and 2 mM
ATP. Reactions were initiated with the addition of 5 l of a solution
containing 50 mM Tris-HCl (pH 8.0), 28.6 nM TbCet1, 0.02 mg/ml bo-
vine serum albumin, 2 mM DTT, 10% glycerol, 0.005% Tween 80. “No-
inhibitor” control reaction mixtures received 1l of 10% DMSO alone in
lieu of test compound. “Complete-inhibition” control reaction mixtures
received 1 l of 400 mM EDTA in 10% DMSO. The plates were covered
and incubated for 1 h at room temperature. The reactions were then
quenched with 40 l of malachite green solution, made by mixing 1 vol-
ume of 0.125% (wt/vol) malachite green in 2 M H2SO4 with 4 volumes of
0.47% (wt/vol) ammonium molybdate in 0.055% (vol/vol) Tween 20. The
quenched plates were incubated for 1 h at room temperature and then
scanned to quantifyA630 for each reaction well.Z= for the assay was gauged
by comparing three 384-well plates of no-inhibitor control reactions with
three 384-well plates of complete-inhibition control reactions. The effect
of any test compound on TbCet1 was quantified by comparison of itsA630
value for Pi release with those of the no-inhibitor (0% inhibition) and
complete-inhibition (100% inhibition) controls. IC50s in the HTS assay
format were determined by testing a series of 12 serial 2-fold dilutions of
the test compound in 10% DMSO.
TLC assay for 32Pi release from [-32P]ATP. Reaction mixtures
(20 l) contained 100 mM Tris-HCl, pH 8.0, 10 mM NaCl, 1% (vol/vol)
glycerol, 2 mM MnCl2, 200 M [-32P]ATP, 5% DMSO, TTM enzymes
(either 2.2 nM TbCet1, 7 nM MimiCE, 25 nM SceCet1, 50 nM Lef4, or
500 nM CthTTM), and inhibitors as specified. The inhibitors were serially
diluted in DMSO, and 1l was included in each ATPase reaction mixture.
The reactions were initiated by addition of enzyme. After incubation for
10 min at 37°C (for TbCet1, MimiCE, Lef4, and CthTTM) or 30°C (for
SceCet1), the reactions were quenched by adjustment to 1 M formic acid.
Aliquots of the mixtures were applied to polyethyleneimine cellulose TLC
plates and analyzed by ascending TLC with 200 mM ammonium sulfate as
the mobile phase. Radiolabeled ATP and Pi were visualized and quantified
by scanning the TLC plate with a Fuji imager. The concentrations of input
enzyme were chosen so as to attain hydrolysis of ~30% of the input ATP
substrate in the “no-inhibitor” control reaction mixtures containing 5%
DMSO. The extents of ATP hydrolysis were plotted versus inhibitor con-
centration after normalization to the “no-inhibitor” control values. IC50s
were obtained using the “dose-response” curve fitting algorithms in
Prism.
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